clopidogrel has been researched along with avapro in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S | 1 |
| Anand, I; Arthur, H; Avezum, A; Bethala-Sithya, M; Blumenthal, M; Budaj, A; Camm, J; Ceremuzynski, L; Chrolavicius, S; Commerford, PJ; Connolly, S; De Caterina, R; Diaz, R; Flaker, G; Flather, M; Fox, KA; Frangin, G; Franzosi, MG; Gaudin, C; Goldhaber, S; Golitsyn, S; Granger, C; Halon, D; Hart, R; Hermosillo, A; Hohnloser, S; Hunt, D; Jansky, P; Joyner, C; Karatzas, N; Keltai, M; Lanas, F; Lau, CP; Le Heuzey, JY; Lewis, BS; Morais, J; Morillo, C; Oto, A; Paolasso, E; Peters, RJ; Pfeffer, M; Pfisterer, M; Piegas, L; Pipillis, T; Proste, C; Sitkei, E; Swedberg, K; Synhorst, D; Talajic, M; Trégou, V; Valentin, V; van Mieghem, W; Varigos, J; Weintraub, W; Yusuf, S | 1 |
| Meinertz, T | 1 |
| Chen, X; Chen, Y; Li, J; Shi, S; Tu, X; Wang, J; Xie, Y | 1 |
| Cairns, JA; Gent, M; Hirsh, J; Marler, J; Pogue, J; Pritchett, EL; Wittes, J; Wyse, DG | 1 |
| Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S | 1 |
| Chen, CP; Seet, RC | 1 |
| Budaj, A; Chrolavicius, S; Connolly, SJ; De Caterina, R; Morais, J; Pogue, J; Renda, G; Yusuf, S | 1 |
| Kamal, AK; Khan, M | 2 |
| Hart, RG | 1 |
| Connolly, SJ; Hart, RG; Healey, JS; Hohnloser, SH; McAlister, FA; Pfeffer, MA; Sandhu, RK; Yuan, F; Yusuf, S | 1 |
| Benavente, O; Connolly, SJ; Hart, RG; Pearce, LA; Perera, KS; Sharma, M | 1 |
3 review(s) available for clopidogrel and avapro
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clinical Trials Data Monitoring Committees; Clopidogrel; Decision Making; Female; Humans; Irbesartan; Male; Prognosis; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Tetrazoles; Ticlopidine; Treatment Outcome | 2008 |
Optimizing antiplatelet therapy in high-risk patients with atrial fibrillation: insights from Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE A).
Topics: Antihypertensive Agents; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Contraindications; Humans; Irbesartan; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Tetrazoles; Ticlopidine; Treatment Outcome | 2009 |
6 trial(s) available for clopidogrel and avapro
| Article | Year |
|---|---|
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Humans; International Normalized Ratio; Irbesartan; Platelet Aggregation Inhibitors; Risk Factors; Severity of Illness Index; Stroke; Tetrazoles; Ticlopidine | 2006 |
Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Double-Blind Method; Female; Humans; Irbesartan; Male; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Research Design; Tetrazoles; Ticlopidine | 2006 |
Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Cerebral Hemorrhage; Clinical Protocols; Clopidogrel; Drug Combinations; Drug Therapy, Combination; Female; Humans; Irbesartan; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome; Warfarin | 2008 |
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
Topics: Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Irbesartan; Kaplan-Meier Estimate; Platelet Aggregation Inhibitors; Risk Factors; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome; Vitamin K | 2010 |
Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Female; Heart Failure; Humans; Irbesartan; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Stroke; Tetrazoles; Thromboembolism; Ticlopidine; Treatment Outcome; Ventricular Dysfunction, Left | 2015 |
Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Clopidogrel; Female; Humans; Irbesartan; Male; Middle Aged; Platelet Aggregation Inhibitors; Predictive Value of Tests | 2018 |
6 other study(ies) available for clopidogrel and avapro
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
[Anticoagulation in atrial fibrillation. ACTIVE Study (Arterial fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events)].
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Intracranial Embolism; Irbesartan; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Tetrazoles; Thromboembolism; Ticlopidine | 2007 |
Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Chronic Disease; Clopidogrel; Creatinine; Hypertension; Irbesartan; Kidney; Kidney Diseases; Nephrectomy; Platelet Aggregation Inhibitors; Rats; Tetrazoles; Ticlopidine; Wounds and Injuries | 2008 |
Atrial fibrillation, is warfarin the only option for stroke prevention?
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Atrial Fibrillation; Biphenyl Compounds; Clinical Trials as Topic; Clopidogrel; Evidence-Based Medicine; Humans; Irbesartan; Platelet Aggregation Inhibitors; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome; Warfarin | 2011 |
Atrial fibrillation, is warfarin the only option for stroke prevention?
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Cerebral Hemorrhage; Clopidogrel; Evidence-Based Medicine; Follow-Up Studies; Humans; Hypertension; Irbesartan; Platelet Aggregation Inhibitors; Stroke; Tetrazoles; Ticlopidine; Treatment Outcome; Warfarin | 2011 |
The unmet need of patients with atrial fibrillation: AVERROES and the novel oral anticoagulants.
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Compounds; Clinical Trials, Phase III as Topic; Clopidogrel; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Irbesartan; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Stroke; Tetrazoles; Ticlopidine | 2011 |